Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)
Twitter
Tags: Biotech

This Blockbuster Drug Has Room to Run

By William Patalon III, Executive Editor, Money Morning • January 19, 2015

View Comments

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

William Patalon IIIWilliam Patalon III

Shares of blood cancer drugmaker Pharmacyclics Inc. (Nasdaq: PCYC) rocketed as much as 22% last Tuesday after the company exhilarated investors by forecasting that sales of its key drug would double this year.

We weren't surprised by this, of course.

But even more important was that Private Briefing readers weren't, either.

In a Private Briefing report back in early December, we said the Pharmacyclics blood cancer drug Imbruvica (ibrutinib) was well on its way to becoming the blockbuster we predicted when we first recommended shares of the Sunnyvale, Calif.-based biotech back in April 2012.

That "call" was right on target.

Late last Monday, after the close of trading, Pharmacyclics said net-product revenue for Imbruvica for full-year 2014 would come in at $492 million. That would include sales of about $185 million in the fourth quarter alone - a hefty "sequential" (quarter-to-quarter) jump of 31%.

But here's the real stunner: For 2015, the company is looking at sales to more than double and reach $1 billion.

Sign up for SMS so you never miss special events, exclusive offers, and weekly bonus trades.
For those who want the actual numbers, that's a gain of 103%.

Imbruvica, you see, is shaping up to be the very blockbuster we told you it would be.

And that bodes well for Pharmacyclics shares.

Let's take a look ...

A Leap... a Jump... and More to Come

Pharmacyclics shares have gained as much as 444% since we recommended them in the April 2012 special research report "The Biotech Buyout Binge."

From our initial recommendation price of $28.47 a share, the stock has soared as high as $154.89.

We re-recommended it back on Dec. 3 - and it closed that day at $139.33.

On Tuesday, Pharmacyclics zoomed as much as $27.28 a share, or 22%, to peak at $150.99.

Although it gave back some of those gains, the stock was still up $20.37 a share, or 16.2%, to $144.08 in late-afternoon trading. That's 3% above our Dec. 3 re-recommendation close - or about 27% on an annualized basis.

Sell-siders right now have a $156 target price on Pharmacyclics. But the estimates go as high as $225 - a potential 68% gain from current levels and 690% above our $28.47-a-share"Buy" price.

And with the company's bullish, just-released projection for Imbruvica, you can bet we'll see a strong "upgrade cycle" - where analysts boost their ratings and target prices for Pharmacyclics. And a concentrated upgrade cycle could be just the catalyst required for the stock to embark on its next rally.

For instance, RBC Analyst Michael Yee boosted his target price from $118 to $130 - only to have the stock blow right through his estimate.

Pharmacyclics is far from our only big win in the biotech sector...

Join the conversation. Click here to jump to comments…

William Patalon IIIWilliam Patalon III

About the Author

Browse William's articles | View William's research services

Before he moved into the investment-research business in 2005, William (Bill) Patalon III spent 22 years as an award-winning financial reporter, columnist, and editor. Today he is the Executive Editor and Senior Research Analyst for Money Morning at Money Map Press.

… Read full bio

Login
guest
guest
2 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
LORI G.
LORI G.
8 years ago

IS RGEN STILL A BUY?

0
Reply
Marc Ledogar
Marc Ledogar
8 years ago

Thanks for the tips, I know you probably do not concern yourself with penny stocks, However EAPH Easton Pharmaceuticals has seen a rise since Dec 30th .0084 to .0315 before settling at .0295 last week and should see even more considerable growth. Also DEWM: Dewmar International A few months ago sitting at .0016 then jumping to .0079 now sitting around .0038 is announcing a new line of hemp drinks. What do you think?

0
Reply


Latest News

June 3, 2023 • By Garrett Baldwin

Postcards - Do This Whenever You See Buffett Buy OXY

June 2, 2023 • By Nick Black

Market Roundup: Digital Assets to Watch for the Weekend of June 2

June 2, 2023 • By Shah Gilani

earnings
How to Profit on a "Bankruptcy Wave" Hitting Markets Hard
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Flashpoint Trader Darknet Hyper Momentum Trader Alpha Accelerators Weekly Profit Cycles Brutus Alerts Resource Traders Alliance

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz